VERASTEM INC

NASDAQ: VSTM (Verastem, Inc.)

Last update: 12 Nov, 2024, 1:44AM

4.46

0.51 (12.91%)

Previous Close 3.95
Open 3.99
Volume 1,897,928
Avg. Volume (3M) 740,944
Market Cap 198,498,992
Price / Sales 13.54
Price / Book 16.31
52 Weeks Range
2.10 (-52%) — 14.22 (218%)
Earnings Date 6 Nov 2024
Operating Margin (TTM) -1,145.05%
Diluted EPS (TTM) -3.14
Total Debt/Equity (MRQ) 128.59%
Current Ratio (MRQ) 3.23
Operating Cash Flow (TTM) -109.35 M
Levered Free Cash Flow (TTM) -32.02 M
Return on Assets (TTM) -47.31%
Return on Equity (TTM) -136.87%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Verastem, Inc. Bearish Bearish

AIStockmoo Score

-1.5
Analyst Consensus 1.0
Insider Activity -5.0
Price Volatility -2.0
Technical Moving Averages 0.0
Technical Oscillators -1.5
Average -1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
VSTM 198 M - - 16.31
RVMD 8 B - - 5.67
IONS 6 B - - 8.72
LGND 2 B - 42.44 2.79
HRMY 2 B - 16.13 3.32
IRON 2 B - - 4.06

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 0.83%
% Held by Institutions 59.93%
52 Weeks Range
2.10 (-52%) — 14.22 (218%)
Price Target Range
7.00 (56%) — 13.00 (191%)
High 13.00 (RBC Capital, 191.48%) Buy
Median 9.00 (101.79%)
Low 7.00 (HC Wainwright & Co., 56.95%) Buy
Average 9.67 (116.82%)
Total 3 Buy
Avg. Price @ Call 3.95
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 19 Dec 2024 7.00 (56.95%) Buy 4.44
18 Oct 2024 7.00 (56.95%) Buy 2.96
Mizuho 19 Dec 2024 9.00 (101.79%) Buy 4.44
RBC Capital 18 Oct 2024 13.00 (191.48%) Buy 2.96
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
CALKINS DANIEL - 4.05 -93 -382
GAGNON ROBERT E. - 4.44 -130 -577
PATERSON DAN - 4.44 -183 -813
STUGLIK BRIAN M - 4.44 -334 -1,483
Aggregate Net Quantity -740
Aggregate Net Value ($) -3,254
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 4.28
Name Holder Date Type Quantity Price Value ($)
CALKINS DANIEL Officer 24 Dec 2024 Sell (-) 28 3.90 109
CALKINS DANIEL Officer 20 Dec 2024 Sell (-) 65 4.19 272
PATERSON DAN Officer 19 Dec 2024 Sell (-) 183 4.44 813
STUGLIK BRIAN M Director 19 Dec 2024 Sell (-) 334 4.44 1,483
GAGNON ROBERT E. Director 19 Dec 2024 Sell (-) 130 4.44 577
Date Type Details
30 Dec 2024 Announcement Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
18 Dec 2024 Announcement Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
26 Nov 2024 Announcement Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
06 Nov 2024 Announcement Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
31 Oct 2024 Announcement Verastem Oncology to Participate in Upcoming Investor Conferences
31 Oct 2024 Announcement Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
17 Oct 2024 Announcement Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
09 Oct 2024 Announcement Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
07 Oct 2024 Announcement Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria